Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 2, 2008, Pages 235-241

  Dickey, D Thomas ^a   Muldoon, Leslie L ^a,b   Doolittle, Nancy D ^a   Peterson, Darryl R ^d   Kraemer, Dale F ^e   Neuwelt, Edward A ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e OREGON STATE UNIVERSITY   (United States)

Author keywords

Chemoprotection; Cisplatin; N acetylcysteine; Rats; Route

Indexed keywords

ACETYLCYSTEINE; CISPLATIN; CREATININE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; HISTOPATHOLOGY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FREE RADICAL SCAVENGERS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; RATS; RATS, LONG-EVANS;

EID: 43749101881     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0597-2     Document Type: Article

References (24)

1. Appenroth D, Winnefeld K, Schroter H, Rost M (1993) Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats. J Appl Toxicol 13:189-192
2. Blakley BW, Cohen JI, Doolittle ND et al (2001) Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope 202:1997-2001
3. Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF (1986) Selective protection against cis-diamminedichloroplatinum (II)-induced toxicity in kidney, gut and bone marrow by diethyldithiocarbamate. Cancer Res 46:2751-2755
4. Borgstrom L, Kagedal B, Paulsen O (1986) Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31:217-222
5. Congreave IA, Berggren M, Jones TW, Dawson J, Moldeus P (1087) Gastrointestinal metabolism of N-acetylcysteine in the rat, including an assay for sulfite in biological systems. Biopharm Drug Dispos 8:377-386
6. Dickey DT, Muldoon LL, Kraemer DF, Neuwelt EA (2004) Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hearing Res 193:25-30
7. Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA (2005) Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314:1052-1058
8. Doolittle ND, Muldoon LL, Brummett RE et al (2001) Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493-500
9. Doolittle N, Lacy C, Tyson R et al (2003) Phase 1 study of N-acetylcysteine administered in the descending aorta in conjunction with carboplatin-based blood-brain barrier disruption (BBBD) in subjects with malignant brain tumors. Abstract from the Society for Neuro-Oncology Eighth Annual Meeting. Neuro-Oncology Doc. 03-1003, September 15, 2003
10. Fishbane S, Durham JH, Marzo K et al (2004) N-acetylcysteine in the prevention of radio-contrast-induced nephropathy. J Am Soc Nephrol 15:251-260
11. Konstantinov S, Topashka-Ancheva M, Karaivanova M et al (1994) Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC. Neoplasma 41:253-258
12. Korver KD, Rybak LP, Whitworth C et al (2002) Round window application of d-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 126(6):683-689
13. Links M, Lewis C (1999) Chemoprotectants. A review of their clinical pharmacology and therapeutic efficacy. Drugs 57:293-308
14. Liu R, Nair D, Ix J, Moore DH et al (2005) N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J General Internal Med 20:193-200
15. Marenzi G, Assanelli E, Marana I et al (2006) N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354:2773-2782
16. Muldoon LL, Pagel MA, Kroll RA et al (2000) Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 6:309-315
17. Neuwelt EA, Brummett RE, Doolittle ND et al (1998) First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 286:77-84
18. Neuwelt EA, Pagel MA, Hasler BP et al (2001) Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 61:7868-7874
19. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL (2004) Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309:594-599
20. Nisar S, Feinfeld DA (2002) N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Ren Fail 24:529-533
21. Shalansky SJ, Pate GE, Levin A et al (2005) N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Heart 91:997-999
22. Sheikh-Hamad D, Timmins K, Jalali Z (1994) Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 8:1640-1644
23. Wu YJ, Muldoon LL, Neuwelt EA (2005) The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312:424-431
24. Zagler A, Azadpour M, Mercado C, Hennekens CH (2006) N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 151:140-145